Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (Rapamune) plus low‑dose cytarabine in older AML/MDS patients
2005-002823-15Phase 2Completed
- Sponsor
- Nottingham University Hospitals
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Nottingham University Hospitals. Primary endpoints: Disease response and Toxicity of sirolimus + low-dose cytarabine. Started Aug 2005; status: completed.
02
Drugs
sirolimuscytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-002823-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002823-15.